Table 1. Characteristic of the included studies.
First author, Year | Country | Disease | No. of patients (Exp/control) | No. of catheters (Exp/control) | Tunneled or nontunneled catheter | No. of catheters days (Exp/control) | Intervention | |
---|---|---|---|---|---|---|---|---|
Exp | Control | |||||||
Sanders 2008[16] | New Zealand | hematology | 34/30 | 34/30 | tunneled | 5000/3537 | 70% ethanol | heparin |
Slobbe 2010[17] | Netherlands | hematology | 376 | 226/222 | tunneled | 14262/13483 | 70% ethanol | 0.9% NaCl |
Broom 2012[18] | Australia | hemodialysis | 25/24 | 25/24 | tunneled | 3614/1834 | 70% ethanol | heparin |
Yang 2013[19] | China | hemodialysis | 20/20 | 20/20 | not reported | not reported | 70% ethanol | heparin |
Sun 2014[20] | China | hemodialysis | 16/16 | 16/16 | tunneled | 4449/4363 | 70% ethanol | heparin |
Worth 2014[21] | Australia | hematology | 42/43 | 42/43 | tunneled | 2216/2657 | 70% ethanol | heparin |
Schoot 2015[22] | Netherlands | pediatric oncology | 153/154 | 153/154 | tunneled | 20916/19915 | 70% ethanol | heparin |
Souweine 2015[23] | France | renal-replacement therapy or plasma exchange | 730/730 | 1106/1066 | nontunneled | 6541/6496 | 60% wt/wt ethanol | 0.9% NaCl |
Salonen 2017[24] | USA | parenteral nutrition | 18/20 | 18/20 | not reported | 2597/ 3125 | 70% ethanol | heparin |
Exp, experimental group; Control, control group